{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:07:45Z","timestamp":1789135665142,"version":"build-2803163510"},"reference-count":46,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":237,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>SDHA germline pathogenic variants confer a lower paraganglioma risk compared with other hereditary paraganglioma genes. Reduced screening for carriers without a personal or family history of SDHA-associated tumors has been proposed; however, supporting data remain limited. This single-institution cohort study addresses this by characterizing SDHA carrier tumor features and long-term screening outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This is a retrospective cohort study with longitudinal surveillance follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical records of patients with an SDHA likely pathogenic or pathogenic germline variant identified between July 2015 and July 2025 in the Family Cancer Assessment Clinic at the University of Utah Huntsman Cancer Institute were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 106 SDHA carriers, 15% had a personal history of an SDHA-associated tumor. Of identified tumors, 47% were metastatic or demonstrated malignant behavior (3\/3 extra-adrenal PPGLs, 4\/5 GISTs, 0\/7 head\/neck PPGLs). No affected carriers had known family history of SDHA-associated tumors, and no cases of multiple related tumors were observed. Most carriers (63%) lacked a personal or family history of SDHA-associated tumors. Over 10 years of high-risk screening, zero previously unidentified SDHA-associated tumors were found.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings align with prior evidence that SDHA variants confer a lower tumor risk than other hereditary PPGL genes, lending support to an SDHA-specific screening approach. However, higher rates of malignant tumor behavior in affected carriers compared with sporadic disease suggest SDHA variants may be impactful in contexts like treatment decision-making. These contrasts highlight that while modifying or forgoing tumor screening may be reasonable for many carriers, a nuanced clinical approach remains essential for this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/eo-26-0048","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:46:07Z","timestamp":1787751967000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-15","source":"Crossref","is-referenced-by-count":0,"title":["Tumor risks and surveillance outcomes in\n                    <i>SDHA<\/i>\n                    variant carriers"],"prefix":"10.1530","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6583-0636","authenticated-orcid":true,"given":"Kelsey","family":"Ellis","sequence":"first","affiliation":[{"name":"Inherited Cancer Research Shared Resource, Huntsman Cancer Institute, University of Utah 1 , , ,","place":["Salt Lake City, Utah, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7220-9014","authenticated-orcid":true,"given":"Daniel","family":"Christensen","sequence":"additional","affiliation":[{"name":"Inherited Cancer Research Shared Resource, Huntsman Cancer Institute, University of Utah 1 , , ,","place":["Salt Lake City, Utah, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Beiringer","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2013 Head and Neck Surgery, University of Utah 2 , , ,","place":["Salt Lake City, Utah, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Naumer","sequence":"additional","affiliation":[{"name":"Inherited Cancer Research Shared Resource, Huntsman Cancer Institute, University of Utah 1 , , ,","place":["Salt Lake City, Utah, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"Vagher","sequence":"additional","affiliation":[{"name":"Inherited Cancer Research Shared Resource, Huntsman Cancer Institute, University of Utah 1 , , ,","place":["Salt Lake City, Utah, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wiggins","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Utah 3 , , ,","place":["Salt Lake City, Utah, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"McCrary","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2013 Head and Neck Surgery, University of Utah 2 , , ,","place":["Salt Lake City, Utah, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Buchmann","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2013 Head and Neck Surgery, University of Utah 2 , , ,","place":["Salt Lake City, Utah, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"2026091109211848000_bib1","doi-asserted-by":"crossref","first-page":"e1917","DOI":"10.1210\/clinem\/dgac014","article-title":"Universal germline panel testing for individuals with pheochromocytoma and paraganglioma produces high diagnostic yield","volume":"107","author":"Horton","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026091109211848000_bib2","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1245\/s10434-013-2942-5","article-title":"Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing","volume":"20","author":"Fishbein","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"2026091109211848000_bib3","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1158\/1078-0432.CCR-17-0547","article-title":"Von Hippel-Lindau and Hereditary pheochromocytoma\/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood","volume":"23","author":"Rednam","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026091109211848000_bib4","volume-title":"Neuroendocrine and Adrenal Tumors. Version 1.2026","author":"National Comprehensive Cancer Network","year":"2026"},{"key":"2026091109211848000_bib5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41574-021-00492-3","article-title":"International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers","volume":"17","author":"Amar","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"2026091109211848000_bib6","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N Engl J Med"},{"key":"2026091109211848000_bib7","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/jmedgenet-2017-105127","article-title":"Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD","volume":"55","author":"Andrews","year":"2018","journal-title":"J Med Genet"},{"key":"2026091109211848000_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/humu.21136","article-title":"Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD","volume":"31","author":"Ricketts","year":"2010","journal-title":"Hum Mutat"},{"key":"2026091109211848000_bib9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1210\/jc.2017-01762","article-title":"Clinical aspects of SDHA-related pheochromocytoma and paraganglioma: a nationwide study","volume":"103","author":"van der Tuin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2026091109211848000_bib10","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1210\/js.2018-00120","article-title":"Pathogenicity and penetrance of germline SDHA variants in pheochromocytoma and paraganglioma (PPGL)","volume":"2","author":"Maniam","year":"2018","journal-title":"J Endocr Soc"},{"key":"2026091109211848000_bib11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/jmedgenet-2018-105427","article-title":"Bayesian approach to determining penetrance of pathogenic SDH variants","volume":"55","author":"Benn","year":"2018","journal-title":"J Med Genet"},{"key":"2026091109211848000_bib12","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00432-017-2397-3","article-title":"SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations","volume":"143","author":"Jochmanova","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026091109211848000_bib13","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3390\/genes14030646","article-title":"SDHA germline mutations in SDH-deficient GISTs: a current update","volume":"14","author":"Schipani","year":"2023","journal-title":"Genes"},{"key":"2026091109211848000_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41698-018-0053-2","article-title":"SDH-deficient renal cell carcinoma associated with biallelic mutation in succinate dehydrogenase A: comprehensive genetic profiling and its relation to therapy response","volume":"2","author":"McEvoy","year":"2018","journal-title":"NPJ Precis Oncol"},{"key":"2026091109211848000_bib15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ejendo\/lvaf191","article-title":"Estimated global prevalence of genetic carriers of hereditary pheochromocytoma-paraganglioma syndrome in a large multiethnic genomic database","volume":"193","author":"Charoenngam","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"2026091109211848000_bib16","article-title":"Prevalence and distribution of unexpected actionable germline pathogenic variants identified on broad-based multigene panel testing among patients with cancer","volume":"8","author":"Landry","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"2026091109211848000_bib17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/jmedgenet-2021-108355","article-title":"UK recommendations for SDHA germline genetic testing and surveillance in clinical practice","volume":"60","author":"Hanson","year":"2023","journal-title":"J Med Genet"},{"key":"2026091109211848000_bib18","article-title":"To screen or not to screen: complexity of SDHA mutation management","volume":"6","author":"Mohamed","year":"2026","journal-title":"Endocr Oncol"},{"key":"2026091109211848000_bib19","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1158\/1078-0432.CCR-24-4354","article-title":"Update on tumor surveillance for children with hereditary pheochromocytoma\/paraganglioma syndromes","volume":"31","author":"Rednam","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026091109211848000_bib20","article-title":"SDHA secondary findings in germline testing: counseling and surveillance considerations","volume":"4","author":"Skefos","year":"2024","journal-title":"Endocr Oncol"},{"key":"2026091109211848000_bib21","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1210\/js.2017-00230","article-title":"Radiological surveillance screening in asymptomatic succinate dehydrogenase mutation carriers","volume":"1","author":"Tufton","year":"2017","journal-title":"J Endocr Soc"},{"key":"2026091109211848000_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejro.2022.100422","article-title":"Radiologic screening and surveillance in hereditary cancers","volume":"9","author":"Clarke","year":"2022","journal-title":"Eur J Radiol Open"},{"key":"2026091109211848000_bib23","article-title":"SDHA-related phaeochromocytoma and paraganglioma: review and clinical management","volume":"31","author":"Kaplan","year":"2024","journal-title":"Endocr Relat Cancer"},{"key":"2026091109211848000_bib24","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1001\/jamaoncol.2017.0223","article-title":"Clinical characterization of the pheochromocytoma and paraganglioma susceptibility genes SDHA, TMEM127, MAX, and SDHAF2 for gene-informed prevention","volume":"3","author":"Bausch","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026091109211848000_bib25","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3390\/genes14030646","article-title":"SDHA germline mutations in SDH-deficient GISTs: a current update","volume":"14","author":"Schipani","year":"2023","journal-title":"Genes"},{"key":"2026091109211848000_bib26","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00330-012-2723-8","article-title":"Psychosocial consequences and severity of disclosed incidental findings from whole-body MRI in a general population study","volume":"23","author":"Schmidt","year":"2013","journal-title":"Eur Radiol"},{"key":"2026091109211848000_bib27","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.suc.2015.05.009","article-title":"Principles of cancer screening and genetics","volume":"95","author":"Pinsky","year":"2015","journal-title":"Surg Clin North Am"},{"key":"2026091109211848000_bib28","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/PPO.0b013e31823e5387","article-title":"The genetics of cancer risk","volume":"17","author":"Pomerantz","year":"2011","journal-title":"Cancer J Sudbury Mass"},{"key":"2026091109211848000_bib29","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamaoncol.2016.0256","article-title":"Molecular subtypes of KIT\/PDGFRA wild-type gastrointestinal stromal tumors: a report from the national institutes of health gastrointestinal stromal tumor clinic","volume":"2","author":"Boikos","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026091109211848000_bib30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fonc.2019.00053","article-title":"Clinical, diagnostic, and treatment characteristics of SDHA-related metastatic pheochromocytoma and paraganglioma","volume":"9","author":"Jha","year":"2019","journal-title":"Front Oncol"},{"key":"2026091109211848000_bib31","doi-asserted-by":"crossref","first-page":"671","DOI":"10.4149\/neo_2018_181208N933","article-title":"A systematic review on the genetic analysis of paragangliomas: primarily focused on head and neck paragangliomas","volume":"66","author":"Guha","year":"2019","journal-title":"Neoplasma"},{"key":"2026091109211848000_bib32","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1210\/clinem\/dgaf584","article-title":"Metastatic disease in phaeochromocytomas and paragangliomas in various genotypes - a systematic review and meta-analysis","volume":"111","author":"Svendsen","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026091109211848000_bib33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/jmedgenet-2020-107656","article-title":"SDHB variant type impacts phenotype and malignancy in pheochromocytoma-paraganglioma","volume":"60","author":"Bayley","year":"2023","journal-title":"J Med Genet"},{"key":"2026091109211848000_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2024.101938","article-title":"Overview of recent guidelines and consensus statements on initial screening and management of phaeochromocytoma and paraganglioma in SDHx pathogenic variant carriers and patients","volume":"39","author":"Lussey-Lepoutre","year":"2025","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2026091109211848000_bib35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41431-020-00758-w","article-title":"Opportunistic genomic screening. Recommendations of the European Society of Human Genetics","volume":"29","author":"de Wert","year":"2021","journal-title":"Eur J Hum Genet"},{"key":"2026091109211848000_bib36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/jso.24331","article-title":"Importance of cost-effectiveness and value in cancer care and healthcare policy","volume":"114","author":"Kang","year":"2016","journal-title":"J Surg Oncol"},{"key":"2026091109211848000_bib37","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1470-2045(09)70145-7","article-title":"Uptake in cancer screening programmes","volume":"10","author":"Weller","year":"2009","journal-title":"Lancet Oncol"},{"key":"2026091109211848000_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2024.101142","article-title":"Consideration of disease penetrance in the selection of secondary findings gene-disease pairs: a policy statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"26","author":"Gordon","year":"2024","journal-title":"Genet Med"},{"key":"2026091109211848000_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2025.101454","article-title":"ACMG SF v3.3 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"27","author":"Lee","year":"2025","journal-title":"Genet Med"},{"key":"2026091109211848000_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2024.101307","article-title":"Primary care provider practices, attitudes, and confidence with hereditary cancer risk assessment and testing: a mixed methods study","volume":"27","author":"Conner","year":"2025","journal-title":"Genet Med"},{"key":"2026091109211848000_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.757212","article-title":"Limited genomics training among physicians remains a barrier to genomics-based implementation of precision medicine","volume":"9","author":"Schaibley","year":"2022","journal-title":"Front Med"},{"key":"2026091109211848000_bib42","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.11080","article-title":"Insurance coverage of germline genetic testing for ovarian, pancreatic, and early-onset colorectal, endometrial, and breast cancers, stratified by self-reported race and ethnicity","volume":"43","author":"Vaccari","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026091109211848000_bib43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.6004\/jnccn.2020.7674","article-title":"How have multigene panels changed the clinical practice of genetic counseling and testing","volume":"19","author":"Pilarski","year":"2021","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"2026091109211848000_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2025.107600","article-title":"Implementation of point-of-care genetic testing for head and neck paragangliomas: early experience and future directions","volume":"168","author":"Beiriger","year":"2025","journal-title":"Oral Oncol"},{"key":"2026091109211848000_bib45","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/OP-25-00154","article-title":"Universal genetic testing for pancreatic cancer: closing the gap on a missed opportunity","volume":"22","author":"Sanoba","year":"2026","journal-title":"JCO Oncol Pract"},{"key":"2026091109211848000_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/jgc4.70143","article-title":"From the ground up: launching GENETECATM (GENetic education and TEsting for CAncer) a point-of-care cancer genetics service at an academic medical center","volume":"34","author":"Kamara","year":"2025","journal-title":"J Genet Couns"}],"container-title":["Endocrine Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-26-0048\/524280\/eo-26-0048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-26-0048\/524280\/eo-26-0048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:21:29Z","timestamp":1789132889000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article\/6\/1\/e260048\/78089\/Tumor-risks-and-surveillance-outcomes-in-SDHA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eo-26-0048","relation":{},"ISSN":["2634-4793"],"issn-type":[{"value":"2634-4793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"e260048"}}